Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07178431 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MB-CART2019.1 in Refractory Multiple Sclerosis

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Feb 28, 2030 to Aug 16, 2030 · Completion date: Dec 30, 2030 to Aug 16, 2030 · Start date changed from estimate of Jan 30, 2026 to Apr 1, 2026 · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Feb 28, 2030 to Aug 16, 2030
    • Completion date: Dec 30, 2030 to Aug 16, 2030
    • Start date changed from estimate of Jan 30, 2026 to Apr 1, 2026
    • Site details revised
  2. Start date: Oct 30, 2025 to Jan 30, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
Trial Details
NCT Number NCT07178431
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Multiple Sclerosis, CAR T Cell Therapy
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov